Careventures
Careventures
  • Home
  • About us
  • Companies
  • Team
  • News

475 Avenue Louise
1050 Brussels (Belgium)
+32 (0) 22 457 105

Rbla. Catalunya 60 Pral. 2ª
08007 Barcelona (Spain)
+34 932 721 320

Linkedin

info@careventures.eu

September 2023

Centogene announces publication establishing Lyso-Gb1 as a predictive biomarker for Gaucher disease patients

Read more
July 2023

Centogene Biodatabank reveals unique genetic variants in world’s largest Niemann-Pick Type C1 disease cohort

Read more
April 2023

A project co-funded by Corus finds a new therapeutic alternative for HER2+ breast cancer

Read more
April 2023

Centogene launches new CentoGenome®, world’s most comprehensive whole genome sequencing solution for diagnosis of rare and neurodegenerative diseases

Read more
March 2023

Corus’ presence at the Dental Tribune’s IDS 2023

Read more
March 2023

Centogene is partnering with IQVIA to improve health outcomes for rare disease patients

Read more
January 2023

Corus expands into the UK with the integration of Byrnes Dental Laboratory

Read more
November 2022

Corus grows in Spain with the acquisition of two laboratories in Seville and Madrid

Read more
October 2022

Centogene reaches 12,500 patient milestone in world’s largest observational study on Parkinson’s disease genetics

Read more
Careventures

Careventures is an independent pan-European private equity firm exclusively dedicated to healthcare.

Contact

475 Avenue Louise
1050 Brussels (Belgium) 
+32 (0) 22 457 105

Rbla. Catalunya 60 Pral. 2ª
08007 Barcelona (Spain) 
+34 932 721 320

info@careventures.eu

Follow us

  • Linkedin

Legal

  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy

©2023 Careventures. All rights reserved.